Emedastine
| Evidence Level: L2 | Predicted Indications: 2 |
Table of Contents
Emedastine: From Allergic Conjunctivitis to Allergic Urticaria
One-Sentence Summary
Emedastine is a selective histamine H1-receptor antagonist, internationally authorised as an ophthalmic antihistamine for allergic conjunctivitis (e.g. Emadine eye drops), though it holds no current UK marketing authorisation. The TxGNN model predicts it may be effective for Allergic Urticaria, with no registered clinical trials but 4 supporting publications, including one randomised controlled trial, currently available.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not licensed in the UK; internationally authorised for allergic conjunctivitis (H1-antihistamine, ophthalmic route) |
| Predicted New Indication | Allergic Urticaria |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L2 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this Evidence Pack (DrugBank MOA field flagged as a data gap). Based on known pharmacology, emedastine is a selective histamine H1-receptor antagonist and antiallergic agent; its efficacy in allergic conjunctivitis has been established internationally, and mechanistically it may be applicable to allergic urticaria, since both conditions are driven by IgE-mediated mast cell degranulation and histamine release.
Allergic conjunctivitis and allergic/chronic idiopathic urticaria share the same underlying histaminergic pathophysiology, differing mainly in the affected tissue (ocular mucosa vs. skin). H1-antihistamines are already the first-line pharmacological class for both conditions, which supports the biological plausibility of the TxGNN prediction. Notably, a published multicentre RCT has already directly tested oral emedastine difumarate against another antihistamine (loratadine) in chronic idiopathic urticaria, lending clinical — not merely mechanistic — support to this repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered (no matches in ClinicalTrials.gov or ICTRP for emedastine + allergic urticaria).
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 17229605 | 2006 | RCT | European Journal of Dermatology | Randomised, double-blind, multicentre trial (n=192) comparing emedastine difumarate 2mg b.i.d. vs. loratadine 10mg o.d. in chronic idiopathic urticaria; emedastine showed significantly greater reduction in body skin involvement and total urticaria symptom score at 1 and 4 weeks |
| 19558341 | 2009 | Review | Expert Opinion on Pharmacotherapy | Reviews emedastine difumarate’s efficacy across allergic rhinitis, conjunctivitis, urticaria, dermatitis and pruritus; notes no adverse cardiovascular effects and minimal anticholinergic activity versus other antihistamines |
| 24720119 | 2013 | Review | Przegląd Lekarski | Analyses discrepancies between urticaria treatment guidelines, SPCs and clinical evidence for antihistamine therapy |
| 14499249 | 2003 | Preclinical | Clinical Immunology | Murine contact-sensitivity model examining effects of antihistamines including emedastine difumarate on eosinophil recruitment into skin, providing mechanistic support for anti-allergic skin effects |
UK Market Information
Emedastine currently holds no MHRA marketing authorisation and is not marketed in the UK (0 licenses on record).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale:
- While one published RCT and supportive mechanistic/review literature suggest plausible efficacy in urticaria, emedastine has no UK marketing authorisation, and critical safety data (SmPC warnings/contraindications) and MOA confirmation are currently missing — a data gap flagged as blocking for safety review.
To proceed, the following is needed:
- SmPC warnings, contraindications and DDI data (currently unavailable)
- Confirmed mechanism of action from DrugBank or primary literature
- A UK regulatory pathway assessment, since the drug is not currently marketed in the UK
- Consideration of a registered clinical trial in allergic/chronic urticaria to supplement the single existing RCT
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.